Why do second-generation antipsychotics generally cause fewer extrapyramidal symptoms than first-generation agents?
Choose an answer, then check it.
Clinical Pharmacology · Antipsychotics and Mood Stabilizers
Second-Generation Antipsychotics
On this page 6 sections
In 30 seconds
Second-generation (atypical) antipsychotics combine dopamine D2 blockade with serotonin 5-HT2A antagonism, which loosens D2 binding enough to cut the movement-disorder risk that plagues first-generation agents. They treat schizophrenia and bipolar disorder, and several are used adjunctively in depression or for irritability in autism. Their trade-off is metabolic: weight gain, dyslipidemia, and new-onset diabetes replace the extrapyramidal burden of older drugs. Clozapine sits apart as the most effective agent for treatment-resistant illness and suicidality, but its neutropenia and myocarditis risks demand dedicated monitoring.
The college version
Shared Mechanism
All antipsychotics block dopamine D2 receptors, which is what controls hallucinations and delusions (positive symptoms) by dampening excess mesolimbic dopamine signaling. First-generation agents bind D2 tightly and non-selectively, which also blocks D2 in the nigrostriatal pathway and produces extrapyramidal symptoms (EPS) — parkinsonism, dystonia, akathisia — and long-term tardive dyskinesia. Second-generation antipsychotics add potent 5-HT2A serotonin antagonism to a comparatively looser, faster-dissociating D2 blockade. Serotonin normally inhibits striatal dopamine release; blocking 5-HT2A disinhibits that release, partially restoring dopamine tone in the nigrostriatal pathway even while D2 receptors are occupied. The net effect is fewer EPS and less tardive dyskinesia than with first-generation drugs, though not zero risk. This combined D2/5-HT2A antagonism also broadens efficacy against negative symptoms (flat affect, social withdrawal) and mood symptoms, which is why these agents extend well beyond schizophrenia.
The Major Agents
Risperidone and its active metabolite paliperidone are potent D2 blockers with a narrower "atypical" margin, so they cause dose-related EPS and notably elevate prolactin — since D2 blockade in the tuberoinfundibular pathway removes dopamine's normal brake on prolactin release, producing galactorrhea, gynecomastia, or menstrual irregularities. Olanzapine and quetiapine are more sedating, with olanzapine carrying the heaviest metabolic burden of the class and quetiapine used at low doses for sedation and insomnia adjacent to its antipsychotic and bipolar-depression roles. Ziprasidone and lurasidone are more metabolically neutral, but ziprasidone prolongs the QT interval and requires attention to other QT-prolonging drugs and electrolyte status. Asenapine is sublingual with its own absorption quirks. Aripiprazole, cariprazine, and brexpiprazole act as D2 partial agonists rather than full antagonists — they stimulate D2 weakly in low-dopamine states and dampen it in high-dopamine states, a "dopamine stabilizer" profile that lowers prolactin and metabolic risk but characteristically produces akathisia (subjective restlessness, an urge to move) more than sedation.
Clozapine: Unique Efficacy, Unique Risk
Clozapine is the only antipsychotic proven superior for treatment-resistant schizophrenia (illness that fails adequate trials of at least two other antipsychotics) and the only one with a specific indication for reducing suicidal behavior in schizophrenia and schizoaffective disorder. Its mechanism includes weaker D2 affinity than any other agent, with broader receptor effects (serotonergic, adrenergic, cholinergic, histaminergic) that likely underlie both its efficacy and its side-effect profile. Its use is restricted by serious risks: severe neutropenia that can progress to agranulocytosis, requiring baseline and ongoing absolute neutrophil count monitoring under a controlled distribution program; myocarditis, especially early in treatment; lowered seizure threshold; significant orthostatic hypotension; and severe constipation that can progress to ileus or bowel obstruction, a risk from strong anticholinergic activity that is easy to underestimate. Because of this risk profile, clozapine is reserved for patients who have not responded to other options despite being the most effective single agent available.
Indications Beyond Schizophrenia
Several second-generation antipsychotics are approved for bipolar mania and for bipolar maintenance therapy, often alongside or instead of a classic mood stabilizer. Quetiapine, lurasidone, and cariprazine have specific roles in bipolar depression, a phase that mood stabilizers alone often manage poorly. Several agents (including aripiprazole, brexpiprazole, and quetiapine) are used adjunctively with antidepressants in major depressive disorder that has not fully responded to an antidepressant alone. Risperidone and aripiprazole are also approved for irritability associated with autism spectrum disorder in children, addressing aggression, self-injury, and severe tantrums rather than core social-communication symptoms.
Metabolic Syndrome and Monitoring
As a class, second-generation antipsychotics carry meaningfully more metabolic risk than first-generation agents: weight gain, dyslipidemia, and impaired glucose regulation that can produce new-onset diabetes, with risk varying by agent (highest with olanzapine and clozapine, lowest with ziprasidone, lurasidone, and aripiprazole). This burden justifies baseline and periodic monitoring in principle — weight/BMI, waist circumference, blood pressure, fasting glucose or hemoglobin A1c, and a lipid panel — checked before starting therapy and at intervals thereafter, so that emerging metabolic disease is caught early rather than after it becomes entrenched.
Formulations and a Boxed Warning
Several agents (risperidone, paliperidone, olanzapine, aripiprazole) are available as long-acting injectables administered every few weeks, which improve adherence for patients who struggle with daily oral dosing and reduce relapse tied to missed doses. Across the entire antipsychotic class, both first- and second-generation, a boxed warning cautions against use in older adults with dementia-related psychosis, reflecting an observed increase in mortality (largely cardiovascular and infectious causes) in that population — these drugs are not approved for that indication and are used there, if at all, only with great caution and clear justification.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of your brain's dopamine system like a radio that's playing too loud in the parts that cause confused thinking. Older antipsychotic medicines turn that dial down hard everywhere, including in the parts of your brain that control smooth movement — so people's muscles get stiff and jerky. Newer ("atypical") antipsychotics also add a second ingredient that acts like a volume-balancer for a different brain chemical, serotonin, which gently gives some of that movement-control dopamine back. Same big benefit for calming confused thoughts, way less stiffness. The catch is these newer medicines can make people hungrier and change how their body handles sugar and fat, so doctors check weight and blood tests regularly. One special medicine in this family, clozapine, works best of all for people other medicines haven't helped, but it needs extra-careful blood monitoring because in rare cases it can lower a type of blood cell that fights infection.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient on risperidone develops galactorrhea and menstrual irregularities. Explain, in terms of receptor pathways, why this happens with risperidone more than with a D2 partial agonist like aripiprazole.
Show answer
Prolactin release is normally held in check by dopamine acting on D2 receptors in one specific brain pathway (tuberoinfundibular).
Risperidone blocks D2 receptors strongly and fairly uniformly, including in that pathway, so dopamine's brake on prolactin gets removed and prolactin rises, causing galactorrhea and cycle changes. A partial agonist like aripiprazole still activates D2 somewhat in that same pathway, so it keeps enough of the brake in place and prolactin stays closer to normal.
A prescriber is choosing among second-generation antipsychotics for a patient who is already overweight with borderline blood sugar, and needs to be able to avoid QT-prolonging drugs. Name one agent that would be a poor fit for the metabolic concern and one that would be a poor fit for the QT concern, and briefly justify each.
Show answer
Olanzapine is a poor fit for the metabolic concern, and ziprasidone is a poor fit for the QT concern.
Olanzapine carries among the highest risk of weight gain, dyslipidemia, and new-onset diabetes in this class, which would worsen an already overweight, borderline-glucose patient. Ziprasidone is specifically associated with QT-interval prolongation, so it conflicts directly with a need to avoid QT-prolonging drugs.
Quick check
3 questions here. Answers stay hidden until you check.
Which agent is uniquely indicated for treatment-resistant schizophrenia and for reducing suicidal behavior, but requires absolute neutrophil count monitoring?
Choose an answer, then check it.
A patient started on aripiprazole reports a new, distressing sense of inner restlessness and an inability to sit still. What is this most likely to be, given aripiprazole's mechanism?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.